Phase 1 N=10 Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Lymphoma, B-Cell
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=224 Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
Anesthesia, General
Primary: Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9 — 2.32 Minutes
Phase 2 N=50 Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain
Pain
Primary: The Primary Goal of This Study is to Compare the Analgesic Effects of a Combination of Morphine and Methadone With Morphine Alone to Determine Synergistic Activity of mu…
Early Phase 1 N=28 D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
Body Dysmorphic Disorder
Primary: Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS) — 19.64; 18.77 units on a scale
Phase 1 N=76 A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Part A: Pharmacokinetics: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCτ) of LY2605541 and Insulin Glargine: Intra-Participant Variability…
Phase 1 N=40 Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot
Acute Heart Failure
Primary: Overall Safety of a Strategy Based on Subcutaneous Delivery of Furosemide in Inpatients and Outpatients as Measured by Number of Adverse Events — 4; 9; 16; 11 participants
Phase 4 N=125 Effect of Pregabalin on Post Operative Pain in Abdominal Hysterectomy Under Spinal Anesthesia With Intrathecal Morphine
Post Operative Pain
Primary: Post Operative Morphine Consumption — 1; 0; 1; 1 mg — p=0.60
Phase 1 N=59 A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Advanced Malignancies
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
N/A N=216 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 91.1; 95.6 percentage of participants
Phase 3 N=388 A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) — -1.61; -1.36 percent of HbA1c — p=0.005
Phase 4 N=198 Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management
Acute Respiratory Distress
Primary: First Pass Success in Patients Undergoing Emergency Intubation, Intubated With Either Direct Larynogoscopy or Video Laryngoscopy Using a C-MAC Device. — 86.3; 92.2…
N/A N=87 Valiant Evo International Clinical Trial
Aortic Aneurysm, Thoracic
Primary: Composite Safety and Effectiveness Endpoint That is Based on the Percentage of Subjects Who Experienced (a) Access and/or Deployment Failures; and/or (b) Major Device…
Phase 3 N=135 Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
Restless Legs Syndrome · Restless Legs Syndrome (RLS)
Primary: Number of Participants With Adverse Events (AEs) Post-conversion From Ropinirole IR to Ropinirole CR Over Period — 9; 14; 10; 11 Participants
Phase 1 N=39 A Phase 1 Study in Patients With Solid Tumors
Solid Tumors
Primary: Recommended Phase 2 Dose
Phase 3 N=1,274 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% — 20.0; 12.2 Months — p=0.0003